LAVAL, QC, Jan. 31 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that James R. Howard-Tripp, President and Chief Executive Officer of the Company, will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York on Wednesday, February 8, 2006 at 3:20 p.m. ET.
Mr. Howard-Tripp’s presentation will focus on Labopharm’s continued progress of the global commercialization of its once-daily formulation of tramadol.
A live webcast of the presentation will be available on Labopharm’s website at www.labopharm.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 14 days.
About Labopharm Inc.
Labopharm Inc. is an international, specialty pharmaceutical company focused on the development of drugs incorporating Contramid(R), the Company’s proprietary advanced controlled-release technology. Labopharm’s lead in-house product, a once-daily formulation of the analgesic tramadol, is marketed in Germany and has received regulatory approval in 21 other European countries. In the U.S., the Company’s NDA for once-daily tramadol is under review at the FDA and the Company has secured a licensing and distribution agreement with Purdue Pharma Products L.P., the premier marketer of long-acting pain medications in that country. The Company’s pipeline includes a combination of in-house and partnered programs with products both in clinical trials and in preclinical development. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the Corporation’s current expectations regarding future events. The forward- looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion of clinical studies, the uncertainties related to the regulatory process and the commercialization of the drug thereafter. Investors should consult the Corporation’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
Labopharm Inc.
CONTACT: At Labopharm Inc., Warren Whitehead, Chief Financial Officer,Tel: (450) 686-1017, ir@labopharm.com; At The Equicom Group, Jason Hogan -Toronto, Investor Relations and Media, Tel: (416) 815-0700,jhogan@equicomgroup.com; At Feinstein Kean Healthcare, Harriet Ullman -United States, Media and Investor Relations, Tel: (617) 577-8110,hullman@fkhealth.com
